EUVIMEDEUVIMED entdecken
Crossref

Close and Enhance the Cancer‐Immunity Cycle by Engineered Dual‐Targeted Nano‐Adaptors

Pengkai Wu, Ziqu Fang, Longhui Wang, Yong Zhu, Weiwei Long, Mingshan Wang, Zhihao Sun, Zulipikaer Wusiman, Qiang Wang, Kaikai Wang, Dan Ding iD, Dengqiu Xu und 1 weitere

Advanced Materials · 2026-03 · 38 (16)

DOI: 10.1002/adma.202521444 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 11.02.2026. Verfasst von Pengkai Wu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery, MOE Innovation Center for Basic Research in Tumor Immunotherapy, Anhui Province Key Laboratory of Tumor Immune M…. Hauptthemen laut MEDLINE: Nanomedicine, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Clinical Research Special Project of Anhui Provincial Department of Science and Technology, Research Program of Anhui Provincial Department of Education, Research Fund of Anhui Institute of translational medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The cancer‐immunity cycle (CIC) provides a conceptual framework for eliciting effective anti‐tumor immune responses by targeting key events in systemic immunity. However, the successful completion of the CIC often requires the coordinated action of multiple therapeutic modalities, necessitating their integration into a unified system to overcome the limitations of conventional combination therapies. Here, we present a multimodal and programmable platform that integrates diverse therapeutic biomolecules into single agents, enabling the construction of versatile nanomedicines and bispecific antibodies through dual‐targeted nano‐adaptor (TNA) nanotechnology to potentiate the CIC. Specifically, TNA nanomedicines target five critical steps within the CIC, including antigen release, dendritic cell (DC) maturation, T‐cell activation, mitigation of T‐cell exhaustion, and tumor cell killing. Meanwhile, TNA bispecific antibodies enhance DC‐T cell interactions to strengthen adaptive immunity and reinforce NK‐tumor cell interactions to promote cytotoxicity. We demonstrate that TNAs elicit robust anti‐tumor immunity, eradicating established tumors and suppressing metastatic dissemination. Owing to their modular and programmable architecture, TNAs hold broad potential for applications in immunotherapy and beyond.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NanomedicineNeoplasmsAnimalsAntibodies, BispecificDendritic CellsCell Line, TumorHumansMiceImmunotherapyT-LymphocytesKiller Cells, Natural

Stichwörter der Autor:innen

bispecific antibodycancer‐immunity cycledual‐targeted nano‐adaptorimmunotherapynanomedicine

Substanzen

Antibodies, Bispecific

Autor:innen und Institutionen

  • Department of Hepatobiliary Surgery, MOE Innovation Center for Basic Research in Tumor Immunotherapy, Anhui Province Key Laboratory of Tumor Immune Microenvironment and Immunotherapy, The First Affiliated Hospital of An…
  • Uygur Medical Hospital of Xinjiang Uygur Autonomous Region (The Second People's Hospital of Xinjiang Uygur Autonomous Region), Urumqi, Xinjiang, China.
  • School of Pharmacy, Nantong University, Nantong, China.
  • Frontiers Science Center for Cell Responses, State Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Bioactive Materials, and College of Life Sciences, Ministry of Education, Nankai University, Tianjin, Ch…

ORCID-Profile: Dan Ding

Förderung

  • Clinical Research Special Project of Anhui Provincial Department of Science and Technology
  • Research Program of Anhui Provincial Department of Education
  • Research Fund of Anhui Institute of translational medicine
  • National Natural Science Foundation of China

Zitieren

APA

Wu, P., Fang, Z., Wang, L., Zhu, Y., Long, W., Wang, M., Sun, Z., Wusiman, Z., Wang, Q., Wang, K., Ding, D., Xu, D., & Sun, B. (2026). Close and Enhance the Cancer‐Immunity Cycle by Engineered Dual‐Targeted Nano‐Adaptors. Advanced Materials, 38(16). https://doi.org/10.1002/adma.202521444

Vancouver

Wu P, Fang Z, Wang L, Zhu Y, Long W, Wang M, et al. Close and Enhance the Cancer‐Immunity Cycle by Engineered Dual‐Targeted Nano‐Adaptors. Advanced Materials. 2026;38(16). doi:10.1002/adma.202521444

BibTeX
@article{Wu2026,
  author = {Wu, Pengkai and Fang, Ziqu and Wang, Longhui and Zhu, Yong and Long, Weiwei and Wang, Mingshan and Sun, Zhihao and Wusiman, Zulipikaer and Wang, Qiang and Wang, Kaikai and Ding, Dan and Xu, Dengqiu and Sun, Beicheng},
  title = {Close and Enhance the Cancer‐Immunity Cycle by Engineered Dual‐Targeted Nano‐Adaptors},
  journal = {Advanced Materials},
  year = {2026},
  volume = {38},
  number = {16},
  doi = {10.1002/adma.202521444}
}
Kostenlos starten →